Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [Graphic News] More Koreans say they plan long-distance trips this year

    [Graphic News] More Koreans say they plan long-distance trips this year
  2. 7

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  3. 8

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  4. 9

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  5. 10

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
소아쌤

Court rules in favor of Celltrion’s Rituxan biosimilar

By 황유미

Published : Aug. 24, 2016 - 16:39

    • Link copied

[THE INVESTOR] Celltrion announced Aug. 24 the Korea Intellectual Property Tribunal found Biogen’s rituximab patent invalid on Aug. 23.

The South Korean biopharmaceutical company contested the move to challenge the validity of Biogen’s patents related to its Rituxan, an original of its cancer-treatment biosimilar Truxima, in 2015. 




Biogen holds three patents related to the blockbuster drug that raked in US$7.3 billion won across the world last year, and this leaves only one out of five patents related to Rituxan, a therapeutic agent for non-Hodgkin lymphoma, valid.

The favorable ruling from the patent scope confirmation trial will help accelerate Celltrion’s plan to launch the rituximab biosimilar in South Korea within this year.

By Hwang You-mee (glamazon@heraldcorp.com)

More from Headlines